According to results from the MOTION study, improvements were seen across several patient-reported outcomes for patients with pulmonary arterial hypertension (PAH) treated with Riociguat (Adempas).

Changes in Living with Pulmonary Hypertension (LPH) from baseline at Week 24 correlated positively with Work Limitations Questionnaire (WLQ-8) and negatively with the Short Form (SF)-12 Health Survey and 6-minute walking distance (6MWD), but weakly correlated with Borg Scale.

“These data suggest that improvements in LPH score, a disease-specific HRQoL assessment tool, correlate with other PROs including SF-12 and WLQ-8 in newly diagnosed, riociguat-treated patients with PAH,” researchers concluded.

Read the abstract here: